1. Introduction {#sec1-molecules-25-02409}
===============

Sleep-disorders are one of the largest public health concerns in the whole world \[[@B1-molecules-25-02409]\]. New functionalized pyrazolo \[3,4-*b*\]pyrrolo\[3,4-*d*\]pyridine derivatives were enthusiastically investigated to develop the increased potency and reduced side effects of novel sedative/hypnotic drug compounds for treatment of sleep-disorders \[[@B2-molecules-25-02409],[@B3-molecules-25-02409]\]. On the other hand, pyrazolopyridopyridazine diones are well-known as the versatile precursors for synthesis of pyrazolopyridopyridazine phosphodiesterase type 5 (PDE5) inhibitors \[[@B4-molecules-25-02409],[@B5-molecules-25-02409]\]. In recent years, chemiluminescent luminol derivatives have been an attractive detection technique in analytical applications such as presumptive test agents for latent blood detection \[[@B6-molecules-25-02409],[@B7-molecules-25-02409],[@B8-molecules-25-02409],[@B9-molecules-25-02409]\], high-performance liquid chromatography (HPLC) \[[@B10-molecules-25-02409],[@B11-molecules-25-02409]\], DNA, immunoassay, and cancer screening detection \[[@B12-molecules-25-02409],[@B13-molecules-25-02409]\]. Since now, many newly designed luminol structures have been enthusiastically investigated to increase the chemiluminescence efficiency, intensity, sensitivity, quantum yield, or the recognition ability of the resulting chemiluminogens ([Figure 1](#molecules-25-02409-f001){ref-type="fig"}) \[[@B14-molecules-25-02409],[@B15-molecules-25-02409],[@B16-molecules-25-02409],[@B17-molecules-25-02409],[@B18-molecules-25-02409],[@B19-molecules-25-02409]\].

Furthermore, *N*-aminophthalimides were considered as phthalazine 1,4-dione tautomeric pairs \[[@B20-molecules-25-02409],[@B21-molecules-25-02409]\]. *N*-Amino maleimides with pyridine heterocycle series also presented as a very important privileged substructure in organic synthesis for preparing diverse biologically active molecules \[[@B22-molecules-25-02409]\]. Typically, the most important pharmacological effects that have been reported are potential antimicrobial \[[@B22-molecules-25-02409]\] and anticancer activities \[[@B23-molecules-25-02409]\]. Herein, we judiciously explore the insertion of pyridazinedione and *N*-Amino maleimide units into the pyrazolopyridine core ring for construction of the new designed luminol structures **6a**--**j** and **7a**--**i** from versatile 1,3-diarylpyrazolopyrrolopyridine-6,8-diones **11**. Observably, we found that the series of pyridazinediones **6a**--**j** would not only provide conjugation systems but also allow to modify the fluorescence intensity and biological activity ([Figure 2](#molecules-25-02409-f002){ref-type="fig"}).

2. Results and Discussion {#sec2-molecules-25-02409}
=========================

Initially, dimethyl 1,3-diphenyl-1*H*-pyrazolo\[3,4-*b*\]pyridine-4,5-dicarboxylate **8** and diethyl 1,3-diphenyl-1*H*-pyrazolo\[3,4-*b*\]pyridine-4,5-dicarboxylate **9** were prepared by following our previously reported literature \[[@B24-molecules-25-02409]\] from *N*,*N*-diisopropylamidinyl pyrazolylimine and chosen as the model substrate for this investigation on the construction of pyrazolopyridopyridazine diones **6a** ([Scheme 1](#molecules-25-02409-sch001){ref-type="scheme"}). Compounds **8** and **9** were reacted with hydrazine hydrate at reflux in methanol or ethanol solution under the basic condition for 24--36 h \[[@B25-molecules-25-02409],[@B26-molecules-25-02409]\]. However, all the efforts for the predominant formation of **6a** were unsuccessful. We also attempted to perform the hydrolysis of ester groups of compounds **8** and **9** under basic conditions to obtain 1,3-diphenyl-1*H*-pyrazolopyridine-4,5-dicarboxylic acid **10 \[[@B27-molecules-25-02409],[@B28-molecules-25-02409]\]**. Subsequently, pyrazolopyridine-4,5-dicarboxylic acid **10** was refluxed with hydrazine in acetic acid to carry out the cyclization for 8 h, but without success ([Scheme 1](#molecules-25-02409-sch001){ref-type="scheme"}).

In other attempts, we preliminarily tried to synthesize 1,3-phenylpyrazolopyrrolopyridine-6,8-dione **11a** from *N*,*N*-diisopropylamidinyl pyrazolylimine with maleimide via our published InCl~3~/silica gel catalyzed hetero Diels-Alder reaction \[[@B29-molecules-25-02409]\]. Subsequently, the resulting compound **11a** was reacted with an excess of hydrazine hydrate in EtOH/H~2~O co-solution at room temperature for \~7 h \[[@B29-molecules-25-02409],[@B30-molecules-25-02409]\]. The formation of the *N*-aminopyrazolopyrrolopyridine dione **7a** was observed in 83% yield as the major product and accompanied with a trace amount of luminol-type pyrazolopyridopyridazine dione **6a** (\<10%, [Scheme 1](#molecules-25-02409-sch001){ref-type="scheme"}). Fortunately, compounds **6a** and **7a** can be successfully and selectively prepared via kinetic and thermodynamic control reactions \[[@B31-molecules-25-02409],[@B32-molecules-25-02409]\].

For further searching optimal conditions, we also prepared 7-methyl-1,3-phenylpyrazolopyrrolopyridine-6,8-dione **12a** \[[@B29-molecules-25-02409]\] and 1,3-diphenylfuropyrazolopyridine-6,8-dione **13a** \[[@B33-molecules-25-02409],[@B34-molecules-25-02409]\] as probes for monitoring cyclization tendency with hydrazine hydrate \[[@B29-molecules-25-02409],[@B30-molecules-25-02409]\]. Most of the compounds **11a**--**13a** were refluxed in neat hydrazine hydrate solution for \~5 h ([Scheme 1](#molecules-25-02409-sch001){ref-type="scheme"} and [Table 1](#molecules-25-02409-t001){ref-type="table"}). The reactions were monitored until the consumption of starting materials **11a**--**13a** by TLC and produced the luminol-type pyrazolopyridopyridazine dione **6a**. Compound **11a** smoothly underwent the cyclization reaction to give luminol-type analogue **6a** in better yield (84%, Entry 1, [Table 1](#molecules-25-02409-t001){ref-type="table"}). However, compounds **12a**--**13a** resulted in 32% and 18% low yields, respectively (Entries 2 and 3, [Table 1](#molecules-25-02409-t001){ref-type="table"}). For further demonstration of reactivity efficiency, compounds **11b**--**c**, **12b**--**c**, and **13b**--**c** bearing various substituents including *o*- and *m*-Cl in *N*-1-phenyl ring and phenyl at *C*-3 position of pyrazole moiety were synthesized and refluxed under the same condition (Entries 4--9, [Table 1](#molecules-25-02409-t001){ref-type="table"}). Based on the experimental data of [Table 1](#molecules-25-02409-t001){ref-type="table"}, the better yields of pyrazolopyridopyridazine dione products **6b**--**c** were provided from 1,3-diarylpyrazolopyrrolopyridine-6,8-diones **11b**--**c** (74% and 71%, Entries 4 and 7, [Table 1](#molecules-25-02409-t001){ref-type="table"}). Unfortunately, 1,3-diaryl-7-methylpyrazolopyrrolopyridine-6,8-diones **12b**--**c** and 1,3-diarylfuropyrazolopyridine-6,8-diones **13b**--**c** showed poor reactivity for the formation of pyrazolopyridopyridazine diones **6b**--**c** (Entries 5--6 and 8--9, [Table 1](#molecules-25-02409-t001){ref-type="table"}).

Furthermore, we applied this reliable procedure to reactants **11d**--**j** bearing *p*-Cl-Ph, *p*-Br-Ph, *p*-Me-Ph, *p*-OMe-Ph, *p*-CN-Ph, *p*-NO~2~-Ph, and *m*-Cl-Ph at the *N*-1 position and phenyl and H at *C*-3 position of pyrazolic ring. Various substituted reactants **11d**--**j** were demonstrated to proceed smoothly. Both electron-donating and electron-withdrawing substituents were all well-tolerated in good yields (69--84%, Entries 10--16, [Table 1](#molecules-25-02409-t001){ref-type="table"}). All of 1,3-diarylpyrazolopyrrolopyridine-6,8-diones **6a**--**j** were fully characterized by spectroscopic methods. For example, compound **6a** presented one singlet at *δ* 9.41 ppm for pyrazolopyridine ring N=C*H*--C=C in ^1^H-NMR and two peaks at *δ* 153.1 and 155.7 ppm for pyridazine dione carbon O=C--NH in ^13^C-NMR spectrum. Its IR absorptions showed peaks at 3161 cm^−1^ for stretching of the --NH group and at 1014 cm^−1^ for stretching of the N--N group.

For the further controlled experiment for photoluminescence study, we also tried to prepare a series of *N*-aminopyrazolopyrrolopyridine diones **7a**--**i** as the comparison cases ([Scheme 2](#molecules-25-02409-sch002){ref-type="scheme"}). Treatment of pyrazolopyrrolopyridine-6,8-diones **11a**--**i** with 5.0 equivalents of hydrazine hydrate in EtOH/H~2~O co-solution was performed in an ice-bath to room temperature for 48 h. The corresponding *N*-aminopyrazolopyrrolopyridine diones **7a**--**i** were obtained in 71--87% yields and characterized by spectroscopic methods. For example, compound **7a** presented one singlet peak at *δ* 8.83 ppm for pyrazolopyridine ring N=C*H*--C=C in ^1^H-NMR and two peaks at *δ* 164.1 and 164.4 ppm for phthalimide moiety carbon O=C--NH in ^13^C-NMR spectrum. Its IR absorptions showed peaks at 3172 and 3276 cm^−1^ for stretching of the --NH~2~ group and at 1014 cm^−1^ for stretching of the N--N group. Due to the structural skeletons being very similar between **6** and **7**, the identify method should be our next future evaluation.

Luminol (**1**), compounds **6a** and **7a** were dissolved in DMSO to prepare a stock solution (1 × 10^−3^ M). Then the stock solutions of compounds **6a** and **7a** were individually diluted to a concentration of 10 μM in the presence of various solvents such as toluene, THF, ethyl acetate (EA), CH~2~Cl~2~, MeCN, acetone, and DMSO. The standard stock solution of luminol (10 μM) was diluted in DMSO solution as the standard sample. The UV--Vis absorption and fluorescence emission spectra of the pyrazolopyridopyridazine dione **6a** and *N*-aminopyrazolopyrrolopyridine dione **7a** compounds in the above-mentioned solution of varying polarities were reported in [Table 2](#molecules-25-02409-t002){ref-type="table"}. The pyrazolopyridopyridazine dione **6a** has better solubility in polar organic solvents, such as DMSO \> THF \> acetone, but *N*-aminopyrazolopyrrolopyridine dione **7a** has the solubility only in highly polar solvents like DMSO. Luminol (**1**) was also measured and used as the standard sample. The UV--Vis absorption spectra of the compounds **6a** and **7a** in all the studied solvents were almost nearly the same; their absorption property is independent of the solvent polarity ([Figure 3](#molecules-25-02409-f003){ref-type="fig"} and [Table 2](#molecules-25-02409-t002){ref-type="table"}). All these compounds exhibit two highly intense absorption maxima peaks. Among these two, the first one was a high energy absorption between 253 nm and 286 nm for **6a** and **7a** probably due to the π−π\* transition of the aryl core \[[@B35-molecules-25-02409]\] while the low energy band between 329 nm and 366 nm is attributed to the intramolecular charge transfer transition (ICT). However, the rigidity in the structure of compounds **6a** and **7a** exhibited the stronger blue-shifted absorption (\~15 nm) than luminol (**1**) in DMSO solution, as shown in [Figure 3](#molecules-25-02409-f003){ref-type="fig"} and [Table 2](#molecules-25-02409-t002){ref-type="table"}. In comparison with **6a** and **7a**, they demonstrated a similar absorption intensity, and compound **6a** has obvious red-shift \~20 nm with respect to **7a**.

Consequently, we investigated the photoluminescence properties of the compounds **6a** and **7a** with luminol (**1**). For the fluorescence spectra, as shown in [Figure 3](#molecules-25-02409-f003){ref-type="fig"} and [Table 2](#molecules-25-02409-t002){ref-type="table"}, both the fluorescence intensity and the maximal position slightly varied depending on the solvent. Compound **6a** displayed a characteristic emission band of the excitation wavelengths between 400 and 600 nm, and the λ~max~s of PL was \~480 nm with the intense greenish-blue fluorescence in [Figure 3](#molecules-25-02409-f003){ref-type="fig"} and [Figure 4](#molecules-25-02409-f004){ref-type="fig"}. For compound **7a**, it's emission spectrum was between 350 and 550 nm, and the λ~max~s of PL was \~450 nm with the intense bluish-green fluorescence in [Figure 3](#molecules-25-02409-f003){ref-type="fig"} and [Figure 4](#molecules-25-02409-f004){ref-type="fig"}. Compounds **6a** and **7a** exhibited a red-shift \~80 nm or \~60 nm as compared to luminol (**1**). Therefore, new luminol analogues **6a** and **7a** were efficiently conjugate and connect two chromophores (pyrazole and pyridine) to lead to an increase of aromaticity and provide the greenish-blue or bluish-green fluorescent materials ([Table 2](#molecules-25-02409-t002){ref-type="table"} and [Figure 4](#molecules-25-02409-f004){ref-type="fig"}) \[[@B36-molecules-25-02409]\]. Particularly, the best positive solvatofluorism phenomenon was presented in CH~2~Cl~2~ solution. It was also beneficial for the visibility of the naked eye due to the bathochromic (red-shift) phenomenon from blue color to green ([Figure 4](#molecules-25-02409-f004){ref-type="fig"}).

Moreover, the maximum of fluorescence wavelength and intensity, as shown in [Figure 3](#molecules-25-02409-f003){ref-type="fig"}, significantly vary with the diluted solvent. Further, we surprisingly observed the more significant solvent effect on compound **6a** when compared with compound **7a**. As shown in [Figure 3](#molecules-25-02409-f003){ref-type="fig"}, similar fluorescence spectra but a significant difference in intensity (∼6 times) were observed in varying solvents. Of note, it was interesting that toluene, THF, EA, and CH~2~Cl~2~ had differences in their polarity (toluene: 0.099, THF: 0.207, EA: 0.228, CH~2~Cl~2~: 0.309, with respect to the reference polarity of DMSO: 0.444) \[[@B37-molecules-25-02409],[@B38-molecules-25-02409]\]. However, for the above solvents, we observed a strong intensity, in comparison to that for protic or/and polar solvent (DMSO). The intensities of fluorescence bands were reversed in protic or/and polar solvents. Therefore, the solvent polarity modulation of fluorescence was quite interesting. It was well studied that amide tautomer of pyrazolopyridopyridazine dione **6a** was efficiently produced in toluene, THF, EA, and CH~2~Cl~2~ solvents \[[@B39-molecules-25-02409],[@B40-molecules-25-02409],[@B41-molecules-25-02409],[@B42-molecules-25-02409],[@B43-molecules-25-02409],[@B44-molecules-25-02409]\]. In alcoholic (protic) and DMSO solvent, there exists competition between intermolecular bonding of the nearest hydrogen with the hydroxyimine tautomer of 6-hydroxypyrazolopyridopyridazin-9-one **6a**. Therefore, different intensities of behavior were observed in different polarity solutions. On the other hand, the different fluorescence intensity between structural isomers **6a** and **7a** was also observed \[[@B45-molecules-25-02409]\]. The aromaticity of compound **6a** possessed the bathochromic shift of fluorescence maximum λ~max~ by 12 nm and ∼4 times significant intensity in CH~2~Cl~2~ solution when compared with compound **7a** ([Table 2](#molecules-25-02409-t002){ref-type="table"} and [Figure 3](#molecules-25-02409-f003){ref-type="fig"}) \[[@B46-molecules-25-02409]\]. However, the intramolecular and intermolecular hydrogen bondings between the amino and carbonyl groups of *N*-aminopyrazolopyrrolopyridine dione **7a** were formed to lead to the poor intensity in solution.

For further investigation of substituent efficiency of compounds **6** and **7** in photoluminescence properties, we synthesized a series of pyrazolopyridopyridazine diones **6a**--**j** and *N*-aminopyrazolopyrrolopyridine diones **7a**--**i** bearing various substituents including *o*-, *m*- and *p*-Cl, *p*-Br, *p*-Me, *p*-OMe, *p*-CN, and *p*-NO~2~ groups in *N*1-phenyl ring of pyrazole moiety. Generally, most of the substituents such as *o*-, *m*- and *p*-Cl, *p*-Br, *p*-Me, and *p*-CN in *N*1-phenyl of pyrazolic ring of compounds **6** possessed the blue-shift phenomenon range \~10 to 30 nm with significant fluorescence intensity when compared with compound **6a**, particularly for **6c** with *meta*-chloro group ([Figure 5](#molecules-25-02409-f005){ref-type="fig"}). For compounds **6g** and **6i** with the strong electron-donating (*p*-OMe) or electron-withdrawing groups (*p*-NO~2~), they exhibited negative photoluminescence properties ([Figure 5](#molecules-25-02409-f005){ref-type="fig"}). While we modified the skeletal structure of pyrazolopyridopyridazine dione **6j**, in which Ph-group was replaced to H atom on *C*-3 position of pyrazolic ring, the blue-shift phenomenon was remarkably observed in photoluminescence spectra. Additionally, the fluorescence intensity of **6j** was significantly promoted about 2.3 times in comparison with compound **6a** ([Figure 5](#molecules-25-02409-f005){ref-type="fig"}). Based on the result of the substituent study, we conceived that compound **6j** was an effective substrate that possessed suitable conjugation conformation without the torsion effect to facilitate the photoluminescence properties \[[@B26-molecules-25-02409]\]. For compounds **7a**--**i** bearing the above various substituents, they provided the weak fluorescence intensity \[[@B45-molecules-25-02409]\] and possessed the blue-shift phenomenon when compared with **7a**, except for **7c** with *m*-chloro group and **7h** with *p*-CN group ([Figure 6](#molecules-25-02409-f006){ref-type="fig"}). Generally, compounds **7a**--**i** were the inappropriate photoluminescent substrates \[[@B45-molecules-25-02409]\].

The quantum yields (Φ~f~) of luminol (**1**) and pyrazolopyridopyridazine diones **6a**, **6c**, and **6j** were measured in the CH~2~Cl~2~ solution using quinine sulfate in 0.05M H~2~SO~4~ (Φ~f~ = 0.60) as the standard (excitation wavelength 350 nm) \[[@B47-molecules-25-02409],[@B48-molecules-25-02409]\]. The quantum yields (Φ~f~) values of luminol (**1**) and pyrazolopyridopyridazine diones **6a**, **6c**, and **6j** were estimated as 0.175, 0.056, 0.067, and 0.140 in CH~2~Cl~2~ solution, respectively, indicating that the Φ~f~ value of **6j** was similar to that of luminol (**1**, [Table 3](#molecules-25-02409-t003){ref-type="table"}). Moreover, we also investigated the quantum yields of **6j** in various solvents by using the same condition. The estimated values order trendy was as 0.218 (THF) \> 0.209 (Toluene) \> 0.140 (CH~2~Cl~2~) \> 0.083 (acetone) \> 0.049 (EA), indicating THF provided the largest Φ~f~ value among them ([Table 3](#molecules-25-02409-t003){ref-type="table"}). On the other hand, most of the quantum yields (Φ~f~) pyrazolopyridopyridazine diones **6a**--**i** in CH~2~Cl~2~ solution were predicted to be an almost identical value (ca. 0.05--0.06). Interestingly, the high Φ~f~ value of **6j** was obtained and possibly caused by a particular improvement in the planar skeletal conformation ([Table 3](#molecules-25-02409-t003){ref-type="table"} and [Figure 7](#molecules-25-02409-f007){ref-type="fig"}).

3. Experimental Section {#sec3-molecules-25-02409}
=======================

3.1. General Information {#sec3dot1-molecules-25-02409}
------------------------

All reagents were used as obtained commercially. All reactions were carried out under argon or nitrogen atmosphere and monitored by thin-layer chromatography (TLC). Flash column chromatography was carried out on silica gel (230--400 mesh). Analytical thin-layer chromatography was performed using pre-coated plates (silica gel 60 F-254) purchased from Merck Inc. Flash column chromatography purification was carried out by gradient elution using *n*-hexane in ethyl acetate (EtOAc) unless otherwise stated. ^1^H-NMR was recorded at 400, 500, or 600 MHz and ^13^C-NMR recorded at 100, 125, or 150 MHz, respectively, in DMSO-*d*~6~ as the solvent. The standard abbreviations s, d, t, q, and m refer to the singlet, doublet, triplet, quartet, and multiplet, respectively. Coupling constant (*J*), whenever discernible, have been reported in Hz. Infrared spectra (IR) were recorded as neat solutions or solids; mass spectra were recorded using electron impact or electrospray ionization techniques. The wavenumbers reported are referenced to the polystyrene 1601 cm^−1^ absorption. ESI-MS analyses were performed on an Applied Biosystems API 300 mass spectrometer. High-resolution mass spectra (HRMS) were recorded on a JEOL JMS-HX110 mass spectrometer with an electron ionization (EI) source The UV-visible absorption and emission spectra were performed on a Perkin-Elmer Lambda 265 and Perkin-Elmer LS50B, a fused quartz cuvette (10 mm × 10 mm) at room temperature, respectively. Quantum yields were obtained by using quinine sulfate (0.60 in 0.05 M H~2~SO~4~) as a reference. Stock solutions (1 × 10^−3^ M) of luminol (**1**), compounds of **6a**--**j** and **7a**--**i** were prepared in dimethyl sulfoxide (DMSO).

3.2. Standard Procedure for Synthesis of Pyrazolopyridopyridazine Diones ***6a***--***j*** {#sec3dot2-molecules-25-02409}
------------------------------------------------------------------------------------------

The reliable procedure involved the treatment of 1,3-diarylpyrazolopyrrolopyridine-6,8-diones (**11a**--**j**), 1,3-diaryl-7-methylpyrazolopyrrolopyridine-6,8-diones (**12a**--**c**) 1,3-diarylfuropyrazolopyridine-6,8-diones (**13a**--**c**, 1.0 equiv.) with hydrazine monohydrate (\~40 equiv.) in neat solution at reflux for 5 h. When the reaction was completed, the reaction mixture was added to water (10 mL) for precipitation. The precipitate was filtered, washed with cold water (10 mL), and *n*-hexane/EA (1/2, 15 mL) to give the corresponding crude pyrazolopyridopyridazine diones **6a**--**j**. The crude desired products **6a**--**j** were recrystallized in acetone/THF (1/4) solution to obtain the pure pyrazolopyridopyridazine diones **6a**--**j** in 11--84% yields. The low solubility of the compounds **6a**--**j** made the ^13^C-NMR characterization of quaternary and carbonyl carbons of these substrates unclear \[[@B25-molecules-25-02409],[@B26-molecules-25-02409]\].

*1,3-Diphenyl-7,8-dihydro-3H-pyrazolo\[4′,3′:5,6\]pyrido\[3,4-d\]pyridazine-6,9-dione* (**6a**), Light yellow solid; yield: 84%; mp 292--295 °C. ^1^H-NMR (DMSO-*d*~6~, 600 MHz) δ 7.43--7.47 (m, 4H, Ar*H*), 7.60--7.64 (m, 4H, Ar*H*), 8.20 (d, *J* = 7.9 Hz, 2H, Ar*H*), 9.43 (s, 1H, Ar*H*), 10.20 (br, 1H, N*H*); ^13^C{^1^H} NMR (DMSO-*d*~6~, 150 MHz) δ 109.55, 122.46 (2 × CH), 126.67, 127.16, 127.78, 129.26 (2 × CH + 2 × CH), 130.21 (2 × CH + CH), 134.99, 138.16, 147.54, 149.49, 151.35, 153.28, 155.21; FT-IR (KBr) *v*: 3161, 3033, 2907, 1662, 1584, 1499, 1414, 1356, 1306, 906 cm^−1^; MS (EI) *m*/*z* (relative intensity): 356 (24), 355 (M^+^, 100), 354 (27), 270 (24), 269 (12), 268 (12), 77 (39); HRMS (EI) *m*/*z*: \[M\]^+^ Calcd for C~20~H~13~N~5~O~2~: 355.1069; found: 355.1065.

*3-(2-Chlorophenyl)-1-phenyl-7,8-dihydro-3H-pyrazolo\[4′,3′:5,6\]pyrido\[3,4-d\]pyridazine-6,9-dione* (**6b**), Yellow-brown solid; yield: 74%; mp 332--335 °C; ^1^H-NMR (DMSO-*d*~6~, 500 MHz) δ 7.40 (br, 3H, Ar*H*), 7.60--7.61 (m, 2H, Ar*H*), 7.63 (d, *J* = 7.5 Hz, 1H, Ar*H*), 7.67 (t, *J* = 7.5 Hz, 1H, Ar*H*), 7.79--7.80 (m, 2H, Ar*H*), 9.35 (s, 1H, Ar*H*); ^13^C{^1^H} NMR (DMSO-*d*~6~, 125 MHz) δ 109.33, 124.53, 126.66, 127.77, 128.01, 128.18, 128.45, 130.23 (2 × CH), 130.30, 130.47, 131.33, 131.36, 134.73, 134.94, 147.84, 149.81, 152.65, 155.49, 156.94; FT-IR (KBr) *v*: 3427, 3281, 3060, 2921, 1621, 1561, 1508, 1430, 1351, 905 cm^−1^; MS (EI) *m*/*z* (relative intensity): 391 (M^+^ + 2, 29), 390 (22), 389 (M^+^, 100), 355 (12), 354 (52), 304 (15), 268 (17), 111 (13), 77 (44); HRMS (EI) *m*/*z*: \[M\]^+^ Calcd for C~20~H~12~ClN~5~O~2~: 389.0680; found: 389.0678.

*3-(3-Chlorophenyl)-1-phenyl-7,8-dihydro-3H-pyrazolo\[4′,3′:5,6\]pyrido\[3,4-d\]pyridazine-6,9-dione* (**6c**), Yellow solid; yield: 71%; mp 228--229 °C; ^1^H-NMR (DMSO-*d*~6~, 500 MHz) δ 7.42--7.43 (m, 3H, Ar*H*), 7.50 (d, *J* = 6.7 Hz, 1H, Ar*H*), 7.60 (d, *J* = 5.2 Hz, 2H, Ar*H*), 7.64 (t, *J* = 8.0 Hz, 1H, Ar*H*), 8.26 (d, *J* = 8.0 Hz, 1H, Ar*H*), 8.34 (s, 1H, Ar*H*), 9.44 (s, 1H, Ar*H*), 12.06 (br, 1H, N*H*); ^13^C{^1^H} NMR (DMSO-*d*~6~, 125 MHz) δ 107.59, 119.56, 120.40, 121.43, 126.72 (3 × CH), 127.93, 130.14 (2 × CH + 1 × C), 130.99, 133.49, 134.67, 139.34, 148.03, 149.66, 151.53, 155.16, 157.57; FT-IR (KBr) *v*: 3453, 3344, 3296, 1651, 1595, 1483 cm^−1^; MS (EI) *m*/*z* (relative intensity): 391 (M^+^ + 2, 33), 390 (27), 389 (M^+^, 100), 388 (14), 304 (14), 111 (11), 77 (17); HRMS (EI) *m*/*z*: \[M\]^+^ Calcd for C~20~H~12~ClN~5~O~2~: 389.0680; found: 389.0686.

*3-(4-Chlorophenyl)-1-phenyl-7,8-dihydro-3H-pyrazolo\[4′,3′:5,6\]pyrido\[3,4-d\]pyridazine-6,9-dione* (**6d**), Light yellow solid; yield: 81%; mp 339--341 °C; ^1^H-NMR (DMSO-*d*~6~, 500 MHz) δ 7.40--7.41 (m, 3H, Ar*H*), 7.58--7.60 (m, 2H, Ar*H*), 7.68 (d, *J* = 8.9 Hz, 2H, Ar*H*), 8.29 (d, *J* = 8.9 Hz, 2H, Ar*H*), 9.41 (s, 1H, Ar*H*); ^13^C{^1^H} NMR (DMSO-*d*~6~, 125 MHz) δ 107.56, 123.52 (2 × CH), 126.60 (2 × CH), 126.64, 127.77, 127.82, 129.23 (2 × CH), 130.18 (2 × CH), 131.06, 134.89, 137.12, 147.88, 149.80, 151.35, 156.76, 157.30; FT-IR (KBr) *v*: 3345, 3206, 1656, 1494, 1446, 1307, 1094, 902 cm^−1^; MS (EI) *m*/*z* (relative intensity): 391 (M^+^ + 2, 36), 390 (31), 389 (M^+^, 100), 388 (20), 354 (12), 304 (19), 268 (11), 111 (15), 77 (24); HRMS (EI) *m*/*z*: \[M\]^+^ Calcd for C~20~H~12~ClN~5~O~2~: 389.0680; found: 389.0687.

*3-(4-Bromophenyl)-1-phenyl-7,8-dihydro-3H-pyrazolo\[4′,3′:5,6\]pyrido\[3,4-d\]pyridazine-6,9-dione* (**6e**), Light yellow solid; yield: 77%;mp 337--339 °C; ^1^H-NMR (DMSO-*d*~6~, 500 MHz) δ 7.40--7.41 (m, 3H, Ar*H*), 7.59 (d, *J* = 5.5 Hz, 2H, Ar*H*), 7.82 (d, *J* = 9.0 Hz, 2H, Ar*H*), 8.25 (d, *J* = 9.0 Hz, 2H, Ar*H*), 9.42 (s, 1H, Ar*H*); ^13^C{^1^H} NMR (DMSO-*d*~6~, 125 MHz) δ 107.67, 119.42, 123.81 (2 × CH), 126.64 (2 × CH), 127.82, 130.16 (2 × CH + C), 132.16 (2 × CH + C), 134.88, 137.56, 147.92, 149.78, 151.36, 157.59, 159.25; FT-IR (KBr) *v*: 3435, 3345, 3266, 1655, 1536, 1492, 1443, 1307, 1094, 916, 902 cm^−1^; MS (EI) *m*/*z* (relative intensity): 436 (24), 435 (M^+^ + 2, 98), 434 (39), 433 (M^+^, 100), 432 (14), 354 (11), 350 (11), 348 (12), 268 (14), 77 (26); HRMS (EI) *m*/*z*: \[M\]^+^ Calcd for C~20~H~12~BrN~5~O~2~: 433.0174; found: 433.0171.

*1-Phenyl-3-(p-tolyl)-7,8-dihydro-3H-pyrazolo\[4′,3′:5,6\]pyrido\[3,4-d\]pyridazine-6,9-dione* (**6f**), Light yellow solid; yield: 84%; mp 346--348 °C; ^1^H-NMR (DMSO-*d*~6~, 500 MHz) δ 2.40 (s, 3H, C*H*~3~), 7.39--7.42 (m, 5H, Ar*H*), 7.58--7.60 (m, 2H, Ar*H*), 8.07 (d, *J* = 8.4 Hz, 2H, Ar*H*), 9.39 (s, 1H, Ar*H*); ^13^C{^1^H} NMR (DMSO-*d*~6~, 125 MHz) δ 20.61, 106.97, 118.99, 122.32 (2 × CH), 126.60 (2 × CH), 127.68, 128.86, 129.60 (2 × CH), 130.21 (2 × CH), 135.09, 135.83, 136.55, 147.26, 149.35, 151.18, 152.87, 155.65; FT-IR (KBr) *v*: 3436, 3345, 3206, 2919, 1656, 1534, 1514, 1480, 1453, 1310, 1096, 903 cm^−1^; MS (EI) *m*/*z* (relative intensity): 370 (25), 369 (M^+^, 100), 368 (16), 354 (14), 284 (18), 91 (15), 77 (19); HRMS (EI) *m*/*z*: \[M\]^+^ Calcd for C~21~H~15~N~5~O~2~: 369.1226; found: 369.1216.

*3-(4-Methoxyphenyl)-1-phenyl-7,8-dihydro-3H-pyrazolo\[4′,3′:5,6\]pyrido\[3,4-d\]pyridazine-6,9-dione* (**6g**), Deep yellow solid; yield: 81%; mp 311--313 °C; ^1^H-NMR (DMSO-*d*~6~, 500 MHz) δ 3.85 (s, 3H, OC*H*~3~), 7.17 (d, *J* = 11.2 Hz, 2H, Ar*H*), 7.43 (s, 3H, Ar*H*), 7.58--7.60 (m, 2H, Ar*H*), 8.03 (d, *J* = 11.2 Hz, 2H, Ar*H*), 9.38 (s, 1H, Ar*H*); ^13^C{^1^H} NMR (DMSO-*d*~6~, 125 MHz) δ 55.49, 106.64, 114.38 (2 × CH), 115.59, 124.31 (2 × CH), 124.60, 126.71 (2 × CH), 127.77, 130.23 (2 × CH), 131.18, 135.03, 147.01, 149.17, 151.12, 152.63, 156.80, 158.33; FT-IR (KBr) *v*: 3435, 3226, 3065, 2886, 1650, 1590, 1535, 1516, 1441, 1362, 1252, 1170, 905 cm^−1^; MS (EI) *m*/*z* (relative intensity): 386 (24), 385 (M^+^, 100), 370 (13), 77 (18); HRMS (EI) *m*/*z*: \[M\]^+^ Calcd for C~21~H~15~N~5~O~3~: 385.1175; found: 385.1180.

*3-(4-Cyanophenyl)-1-phenyl-7,8-dihydro-3H-pyrazolo\[4′,3′:5,6\]pyrido\[3,4-d\]pyridazine-6,9-dione* (**6h**), Yellow solid; yield: 73%; mp 344--347 °C; ^1^H-NMR (DMSO-*d*~6~, 500 MHz) δ 7.43--7.44 (m, 3H, Ar*H*), 7.60--7.61 (m, 2H, Ar*H*), 8.08 (d, *J* = 6.6 Hz, 2H, Ar*H*), 8.56 (d, *J* = 6.6 Hz, 2H, Ar*H*), 9.45 (s, 1H, Ar*H*); ^13^C{^1^H} NMR (DMSO-*d*~6~, 125 MHz) δ 108.84, 118.51, 121.39, 121.70 (2 × CH), 126.74 (2 × CH), 128.07, 128.63, 130.08 (2 × CH), 130.15, 133.62 (2 × CH), 134.51, 141.67, 148.75, 149.75, 151.87, 155.15, 156.71; FT-IR (KBr) *v*: 3397, 3284, 3056, 2228, 1606, 1569, 1516, 1430, 1400, 1317, 905 cm^−1^; MS (EI) *m*/*z* (relative intensity): 381 (26), 380 (M^+^, 100), 379 (23), 295 (17), 102 (13), 77(29); HRMS (EI) *m*/*z*: \[M\]^+^ Calcd for C~21~H~12~N~6~O~2~: 380.1022; found: 380.1030.

*3-(4-Nitrophenyl)-1-phenyl-7,8-dihydro-3H-pyrazolo\[4′,3′:5,6\]pyrido\[3,4-d\]pyridazine-6,9-dione* (**6i**), Yellow solid; yield: 69%; mp 340--342 °C; ^1^H-NMR (DMSO-*d*~6~, 500 MHz) δ 7.41--7.44 (m, 3H, Ar*H*), 7.61 (d, *J* = 6.3 Hz, 2H, Ar*H*), 8.48 (d, *J* = 8.3 Hz, 2H, Ar*H*), 8.67 (d, *J* = 8.3 Hz, 2H, Ar*H*), 9.47 (s, 1H, Ar*H*), 12.11 (br, 1H, N*H*); ^13^C{^1^H} NMR (DMSO-*d*~6~, 125 MHz) δ 113.65, 121.61 (2 × CH), 124.52, 125.13 (2 × CH), 126.85 (2 × CH), 128.22, 130.12 (2 × CH), 130.27, 134.47, 143.27, 145.04, 149.17, 149.92, 152.09, 154.07, 158.18; FT-IR (KBr) *v*: 3435, 1637, 1596, 1522, 1341, 1112, 905 cm^−1^; MS (EI) *m*/*z*(relative intensity): 401 (23), 400 (M^+^, 100), 370 (22), 315 (11), 77(19); HRMS (EI) *m*/*z*: \[M\]^+^ Calcd for For C~20~H~12~N~6~O~4~: 400.0920; found: 400.0919.

*3-(3-Chlorophenyl)-7,8-dihydro-3H-pyrazolo\[4′,3′:5,6\]pyrido\[3,4-d\]pyridazine-6,9-dione* (**6j**), Light yellow solid; yield: 71%; mp 351--352 °C; ^1^H-NMR (DMSO-*d*~6~, 500 MHz) δ 7.51 (d, *J* = 8.03 Hz, 1H, Ar*H*), 7.66 (t, *J* = 8.0 Hz, 1H, Ar*H*), 8.28 (d, *J* = 8.0 Hz, 1H, Ar*H*), 8.39 (s, 1H, Ar*H*), 8.88 (s, 1H, Ar*H*), 9.40 (s, 1H, Ar*H*), 10.20 (br, 1H, N*H*); ^13^C{^1^H} NMR (DMSO-*d*~6~, 125 MHz) δ 109.53, 119.80, 120.84, 126.68 (2 × C), 131.14 (CH + C), 133.57, 136.04, 139.62, 149.36, 150.78, 152.47, 155.87; FT-IR (KBr) *v*: 3433, 3294, 3168, 2974, 1639, 1594, 1568, 1487, 1448, 1274, 1218, 1125 cm^−1^; MS (EI) *m*/*z* (relative intensity): 315 (M^+^ + 2, 35), 314 (28), 313 (M^+^, 100), 278 (12), 255 (13), 227 (21), 111(12), 75 (11); HRMS (EI) *m*/*z*: \[M\]^+^ Calcd for C~14~H~8~ClN~5~O~2~: 313.0367; found: 313.0367.

3.3. Standard Procedure for Synthesis of N-Aminopyrazolopyrrolopyridine Diones (***7a***--***i***) {#sec3dot3-molecules-25-02409}
--------------------------------------------------------------------------------------------------

The reliable procedure involved the treatment of 1,3-diarylpyrazolopyrrolopyridine-6,8-diones (**11a**--**i**, 1.0 equiv.) with hydrazine monohydrate (\~5.0 equiv.) in EtOH/H~2~O (2.0 mL/2.0 mL) in ice-bath to room temperature within 48 h. When the reaction was completed, the reaction mixture was added to water (10 mL) for precipitation. The precipitate was filtered, washed with cold water (10 mL) and *n*-hexane/EA (1/2, 15 mL) to give the corresponding crude *N*-aminophthalimides **7a**--**i**. The crude desired products **7a**--**i** were recrystallized in acetone/THF (1/4) solution to obtain the pure *N*-aminophthalimides **7a**--**i** in 71--87 % yields \[[@B31-molecules-25-02409],[@B32-molecules-25-02409]\].

*7-Amino-1,3-diphenylpyrazolo\[3,4-b\]pyrrolo\[3,4-d\]pyridine-6,8-(3H,7H)-dione* (**7a**), White solid; yield: 83%; mp 217--219 °C; ^1^H-NMR (DMSO-*d*~6~, 400 MHz) δ 4.55 (br, 2H, N*H*~2~), 7.42 (t, *J* = 7.5 Hz, 1H, Ar*H*), 7.49--7.55 (m, 3H, Ar*H*), 7.60--7.65 (m, 4H, Ar*H*), 8.25 (d, *J* = 8.1 Hz, 2H, Ar*H*), 8.82 (s, 1 H, Ar*H*); ^13^C{^1^H} NMR (DMSO-*d*~6~, 100 MHz) δ 111.65, 121.43 (2 × CH), 123.37, 126.80, 128.27 (2 × CH), 128.58 (2 × CH), 128.96, 129.41 (2 × CH), 132.04, 138.44, 139.23, 146.02, 148.82, 150.61, 164.18, 164.49; FT-IR (KBr) *v*: 3275, 3208, 3172, 3035, 1633.0, 1572, 1518.7, 1501 cm^−1^; MS (EI) *m*/*z* (relative intensity): 356 (20), 355 (M^+^, 100), 354 (18), 270 (13), 77.0(18); HRMS (EI) *m*/*z*: \[M\]^+^ Calcd for C~20~H~13~N~5~O~2~: 355.1069; found: 355.1060.

*7-Amino-3-(2-chlorophenyl)-1-phenylpyrazolo\[3,4-b\]pyrrolo\[3,4-d\]pyridine-6,8-(3H,7H)-dione* (**7b**), Yellow solid; yield: 71%; mp 165--166 °C; ^1^H-NMR (DMSO-*d*~6~, 500 MHz) δ 4.52 (br, 2H, N*H*~2~), 7.48 (d, *J* = 7.0 Hz, 1H, Ar*H*), 7.52 (d, *J* = 7.1 Hz, 2H, Ar*H*), 7.60--7.68 (m, 4H, Ar*H*), 7.74 (d, *J* = 7.7 Hz, 1H, Ar*H*), 7.79 (d, *J* =7.7 Hz, 1H, Ar*H*), 8.71 (s, 1H, Ar*H*); ^13^C{^1^H} NMR (DMSO-*d*~6~, 125 MHz) δ 108.50, 122.16, 122.88, 123.33, 127.72 (2 × CH), 129.27 (3 × CH), 129.72 (2 × CH), 131.26, 131.46, 136.60, 136.98, 143.86, 145.72, 153.20, 166.81, 168.47; FT-IR (KBr) *v*: 3337, 3296, 2952, 2920, 1778, 1740, 1498, 1375, 1315, 1014 cm^−1^; MS (EI) *m*/*z* (relative intensity): 391 (M^+^ + 2, 32), 390 (22), 389 (M^+^, 100), 355 (18), 354 (90), 304 (12), 268 (11), 77 (18); HRMS (EI) *m*/*z*: \[M\]^+^ Calcd for C~20~H~12~ClN~5~O~2~: 389.0680; found: 389.0672.

*7-Amino-3-(3-chlorophenyl)-1-phenylpyrazolo\[3,4-b\]pyrrolo\[3,4-d\]pyridine-6,8-(3H,7H)-dione* (**7c**), Yellow solid; yield: 73%; mp 173--175 °C; ^1^H-NMR (DMSO-*d*~6~, 400 MHz) δ 4.55 (br, 2H, N*H*~2~), 7.47--7.54 (m, 4H, ArH), 7.64--7.67 (m, 3H, ArH), 8.31 (d, *J* = 8.9 Hz, 1H, Ar*H*), 8.42 (s, 1H, Ar*H*), 8.86 (s, 1H, Ar*H*); ^13^C{^1^H} NMR (DMSO-*d*~6~, 100 MHz) δ 112.05, 119.33, 120.34, 123.72, 126.32, 128.28 (2 × CH), 128.57 (2 × CH), 129.11, 131.21, 131.73, 133.65, 139.41, 139.64, 146.61, 148.98, 150.72, 163.96, 164.33; FT-IR (KBr) *v*: 3264, 3168, 3034, 1649, 1614, 1595, 1488, 1431, 1300, 803 cm^−1^; MS (EI) *m*/*z* (relative intensity): 391 (M^+^ + 2, 33), 390 (24), 389 (M^+^, 100), 374 (13), 304 (11), 77 (14); HRMS (EI) *m*/*z*: \[M\]^+^ Calcd for C~20~H~12~ClN~5~O~2~: 389.0680; found: 389.0688.

*7-Amino-3-(4-chlorophenyl)-1-phenylpyrazolo\[3,4-b\]pyrrolo\[3,4-d\]pyridine-6,8-(3H,7H)-dione* (**7d**), Light yellow solid; yield: 81%; mp 226--227 °C; ^1^H-NMR (DMSO-*d*~6~, 500 MHz) δ 4.55 (br, 2H, N*H*~2~), 7.48--7.55 (m, 3H, Ar*H*), 7.64 (d, *J* = 7.6 Hz, 2H, Ar*H*), 7.69 (d, *J* = 8.4 Hz, 2H, Ar*H*), 8.35 (d, *J* = 8.4 Hz, 2H, Ar*H*), 8.84 (s, 1 H, Ar*H*); ^13^C{^1^H} NMR (DMSO-*d*~6~, 125 MHz) δ 111.85, 122.54 (2 × CH), 123.55, 128.24 (2 × CH), 128.53 (2 × CH), 129.03, 129.36 (2 × CH), 130.67, 131.81, 137.31, 139.34, 146.35, 148.88, 150.57, 163.99, 164.34; FT-IR (KBr) *v*: 3275, 3207, 3170, 1633, 1499, 828 cm^−1^; MS (EI) *m*/*z* (relative intensity): 391 (M^+^ + 2, 34), 390 (28), 389 (M^+^, 100), 388 (15), 304 (12), 77 (13); HRMS (EI) *m*/*z*: \[M\]^+^ Calcd for C~20~H~12~ClN~5~O~2~: 389.0680; found: 389.0686.

*7-Amino-3-(4-bromophenyl)-1-phenylpyrazolo\[3,4-b\]pyrrolo\[3,4-d\]pyridine-6,8-(3H,7H)-dione* (**7e**), Yellow solid; yield: 79%; mp 235--239 °C; ^1^H-NMR (DMSO-*d*~6~, 500 MHz) δ 4.55 (br, 2H, N*H*~2~), 7.49--7.55 (m, 3H, Ar*H*), 7.64 (d, *J* = 6.9 Hz, 2H, Ar*H*), 7.82 (d, *J* = 8.7 Hz, 2H, Ar*H*), 8.29 (d, *J* = 8.7 Hz, 2H, Ar*H*), 8.84 (s, 1 H, Ar*H*); ^13^C{^1^H} NMR (DMSO-*d*~6~, 125 MHz) δ 111.91, 118.95, 122.81 (2 × CH), 123.55, 128.25 (2 × CH), 128.54 (2 × CH), 129.04, 131.80, 132.28 (2 × CH), 137.75, 139.33, 146.40, 148.90, 150.59, 164.00, 164.35; FT-IR (KBr) *v*: 3275, 3208, 3170, 3071, 3037, 1632, 1495, 826 cm^−1^; MS (EI) *m*/*z* (relative intensity): 436 (22), 435 (M^+^ + 2, 100), 354 (33), 433 (M^+^, 99), 432 (12), 420 (19), 419 (11), 418 (19), 354 (11), 350 (10), 348 (11), 268 (17), 77 (26); HRMS (EI) *m*/*z*: \[M\]^+^ Calcd for C~20~H~12~BrN~5~O~2~: 433.0174; found: 433.0171.

*7-Amino-1-phenyl-3-(p-tolyl)pyrazolo\[3,4-b\]pyrrolo\[3,4-d\]pyridine-6,8-(3H,7H)-dione* (**7f**), Yellow solid; yield: 86%; mp 232--233 °C; ^1^H-NMR (DMSO-*d*~6~, 500 MHz) δ 2.40 (s, 3H, C*H*~3~), 4.55 (br, 2H, N*H*~2~), 7.42 (d, *J* = 8.0 Hz, 2H, Ar*H*), 7.49 (d, *J* = 7.3 Hz, 1H, Ar*H*), 7.52 (t, *J* = 7.3 Hz, 2H, Ar*H*), 7.64 (d, *J* = 7.3 Hz, 2H, Ar*H*), 8.12 (d, *J* = 8.0 Hz, 2H Ar*H*), 8.81 (s, 1H, Ar*H*); ^13^C{^1^H} NMR (DMSO-*d*~6~, 125 MHz) δ 20.63, 111.44, 121.35(2 × CH), 123.18, 128.21 (2 × CH), 128.54 (2 × CH), 128.85, 129.73 (2 × CH), 132.09, 136.06, 136.18, 139.13, 145.69, 148.72, 150.44, 164.20, 164.50; FT-IR (KBr) *v*: 3276, 3209, 3171, 3032, 1634, 1517 cm^−1^; MS (EI) *m*/*z* (relative intensity): 370 (25), 369 (M^+^, 100), 368 (13), 354 (21), 284 (12), 207 (10), 91.1(11), 77.1(13); HRMS (EI) *m*/*z*: \[M\]^+^ Calcd for C~21~H~15~N~5~O~2~: 369.1226; found: 369.1231.

*7-Amino-3-(4-methoxyphenyl)-1-phenylpyrazolo\[3,4-b\]pyrrolo\[3,4-d\]pyridine-6,8-(3H,7H)-dione* (**7g**), Yellow solid; yield: 87%; mp 331--332 °C; ^1^H-NMR (DMSO-*d*~6~, 500 MHz) δ 3.83 (s, 3H, OC*H*~3~), 4.53 (br, 2H, N*H*~2~), 7.17 (d, *J* = 8.7 Hz, 2H, Ar*H*), 7.48--7.53 (m, 3H, Ar*H*), 7.62 (d, *J* = 7.1 Hz, 2H, Ar*H*), 8.06 (d, *J* = 8.7 Hz, 2H, Ar*H*), 8.78 (s, 1H, ArH); ^13^C{^1^H} NMR (DMSO-*d*~6~, 125 MHz) δ 55.64, 111.24, 114.62 (2 × CH), 123.14, 123.51 (2 × CH), 128.37 (2 × CH), 128.65 (2 × CH), 128.97, 131.60, 132.25, 139.14, 145.54, 148.83, 150.44, 158.16, 164.43, 164.73; FT-IR (KBr) *v*: 3215, 3066, 3004, 2963, 2935, 2837, 1639, 1577, 1516, 1462, 1443, 1252 cm^−1^; MS (EI) *m*/*z* (relative intensity): 386 (21), 385 (M^+^, 100), 370 (14), 77.0(10); HRMS (EI) *m*/*z*: \[M\]^+^ Calcd for C~21~H~15~N~5~O~3~: 385.1175; found: 385.1182.

*7-Amino-3-(4-cyanophenyl)-1-phenylpyrazolo\[3,4-b\]pyrrolo\[3,4-d\]pyridine-6,8-(3H,7H)-dione* (**7h**), Yellow solid; yield: 73%; mp 333--335 °C; ^1^H-NMR (DMSO-*d*~6~, 500 MHz) δ 4.55 (br, 2H, N*H*~2~), 7.50--7.55 (m, 3H, Ar*H*), 7.65 (d, *J* = 7.1 Hz, 2H, Ar*H*), 8.09 (d, *J* = 8.5 Hz, 2H, Ar*H*), 8.61 (d, *J* = 8.5 Hz, 2H, Ar*H*), 8.87 (s, 1 H, Ar*H*); ^13^C{^1^H} NMR (DMSO-*d*~6~, 125 MHz) δ 108.41, 112.58, 118.68, 120.75 (2 × CH), 124.12, 128.35 (2 × CH), 128.59 (2 × CH), 129.33, 131.55, 133.84 (2 × CH), 139.53, 141.99, 147.47, 149.11, 151.12, 163.83, 164.27; FT-IR (KBr) *v*: 3330, 3274, 2227, 1665, 1635, 1607, 1518, 1409, 1255, 844 cm^−1^; MS (EI) *m*/*z* (relative intensity): 381 (22), 380 (M^+^, 100), 379 (18), 295 (13), 77(14); HRMS (EI) *m*/*z*: \[M\]^+^ Calcd for C~21~H~12~N~6~O~2~: 380.1022; found: 380.1023.

*7-Amino-3-(4-nitrophenyl)-1-phenylpyrazolo\[3,4-b\]pyrrolo\[3,4-d\]pyridine-6,8-(3H,7H)-dione* (**7i**), Yellow solid; yield: 74%; mp 281--282 °C; ^1^H-NMR (DMSO-*d*~6~, 500 MHz) δ 7.53--7.57 (m, 3H, Ar*H*), 7.93 (d, *J* = 6.5 Hz, 2H, Ar*H*), 8.48 (d, *J* = 9.2 Hz, 2H, Ar*H*), 8.67 (d, *J* = 9.2 Hz, 2H, Ar*H*), 9.19 (s, 1H, Ar*H*); ^13^C{^1^H} NMR (DMSO-*d*~6~, 125 MHz) δ 109.57, 121.41 (2 × CH), 123.52, 125.21 (2 × CH), 127.91 (2 × CH), 129.73, 129.90 (2 × CH), 131.21, 136.89, 143.24, 144.26, 145.12, 147.11, 153.90, 166.71, 168.43; FT-IR (KBr) *v*: 3190, 3120, 3064, 1595, 1500, 1341, 1112, 857 cm^−1^; MS (EI) *m*/*z* (relative intensity): 400 (M^+^, 4), 386 (26), 385 (100), 338 (13), 236 (10), 77 (13); HRMS (EI) *m*/*z*: \[M\]^+^ Calcd for C~20~H~12~N~6~O~4~: 400.0920; found: 400.0925.

3.4. Determination of the Fluorescence Quantum Yield {#sec3dot4-molecules-25-02409}
----------------------------------------------------

The fluorescence quantum yield Φ~x~ was determined through the comparative method. The quinine sulfate (Φ~st~ = 0.60, λ~ex~= 350 nm) in H~2~SO~4~ 0.05 M was used as the standard, and it was calculated by following equation \[[@B48-molecules-25-02409]\]: where st: standard; x: sample; Φ: quantum yield; A: absorbance at the excitation wavelength; D: area under the fluorescence spectra on an energy scale; n: the refractive index of the solution. In the process of detection, the absorbance should be controlled and lower than 0.1.

4. Conclusions {#sec4-molecules-25-02409}
==============

Pyrazolopyridopyridazine diones **6** and *N*-aminopyrazolopyrrolopyridine diones **7** can be prepared in three synthesis methods from 1,3-diarylpyrazolopyrrolopyridine-6,8-diones, 1,3-diaryl-7-methylpyrazolopyrrolopyridine-6,8-diones, or 1,3-diarylfuropyrazolopyridine-6,8-diones with hydrazine monohydrate. Based on the experimental results, 1,3-diarylpyrazolopyrrolopyridine-6,8-diones were conceived as the best reactive starting materials. Furthermore, compounds **6** and **7** were also selectively synthesized under kinetic and thermodynamic control reactions. For the further photoluminescence, solvatofluorism, and quantum yield (Φ~f~) studies, pyrazolopyridopyridazine diones **6** generally exhibited the stronger fluorescence intensity and possessed the significant substituent effect, particularly for **6c** with a *m*-chloro group. On the other hand, the best Φ~f~ value of **6j** was obtained (Φ~f~ = 0.140) and similar to luminol (**1**, Φ~f~ = 0.175), possibly caused by the planar skeletal conformation. Based on the above photoluminescence studies, we also found that the efficient introduction of the pyrazole and pyridine chromophores led to an increase in the conjugation and aromaticity of compounds **6** and **7** when compared with the standard luminol.
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![Luminol **1**, naphthalene and anthracene **2**, quinoxaline analogues of luminol **3**, isoluminol **4**, and benzimidazole analogues of luminol **5**.](molecules-25-02409-g001){#molecules-25-02409-f001}

![Pyrazolopyridopyridazine diones **6a**--**j** and *N*-Aminopyrazolopyrrolopyridine diones **7a**--**i** as luminol analogues.](molecules-25-02409-g002){#molecules-25-02409-f002}

![Synthesis study of pyrazolopyridopyridazine dione **6a** as luminol analogue.](molecules-25-02409-sch001){#molecules-25-02409-sch001}

![The results of *N*-aminopyrazolopyrrolopyridine diones **7a**--**i** from pyrazolopyrrolopyridine-6,8-diones **11a**--**i** with hydrazine hydrate.](molecules-25-02409-sch002){#molecules-25-02409-sch002}

![Photoluminescence spectra of luminol (**1**), pyrazolopyridopyridazine dione **6a** and *N*-aminopyrazolopyrrolopyridine dione **7a** in the different solvents. (**A**) Absorption and (**B**) emission spectra of luminol (**1**) and compound **6a**. (**C**) Absorption and (**D**) emission spectra of compound **7a**.](molecules-25-02409-g003){#molecules-25-02409-f003}

![Color pictures of the fluorescence of compounds **6a** and **7a** in various solvents under excitation at 365 nm.](molecules-25-02409-g004){#molecules-25-02409-f004}

![Photoluminescence spectra of pyrazolopyridopyridazine diones **6a**--**j** dissolved in DMSO to prepare a stock solution (1.0 mM). Then the stock solutions were diluted with CH~2~Cl~2~ to a concentration of 10 μM. (**A**) Absorption and (**B**) emission spectra of compounds **6a**--**j**.](molecules-25-02409-g005){#molecules-25-02409-f005}

![Photoluminescence spectra of *N*-aminopyrazolopyrrolopyridine diones **7a**--**i** dissolved in DMSO to prepare a stock solution (1.0 mM). Then the stock solutions were diluted with CH~2~Cl~2~ to a concentration of 10 μM. (**A**) Absorption and (**B**) emission spectra of compounds **7a**--**i**.](molecules-25-02409-g006){#molecules-25-02409-f006}

![Normalized fluorescence spectra of luminol and pyrazolopyridopyridazine diones **6a**, **6c**, and **6j** in the CH~2~Cl~2~ solution (excitation wavelength 350 nm).](molecules-25-02409-g007){#molecules-25-02409-f007}
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###### 

The results of pyrazolopyridopyridazine diones **6a**--**j** from reactants **11a**--**j**, **12a**--**c**, or **13a**--**c** with hydrazine hydrate.

![](molecules-25-02409-i001)

  Entry   S.M.      X     Y              Z    Reaction Time   Products   Yields (%)
  ------- --------- ----- -------------- ---- --------------- ---------- ------------
  1       **11a**   NH    Ph             Ph   5               **6a**     84
  2       **12a**   NMe   Ph             Ph   5               **6a**     32
  3       **13a**   O     Ph             Ph   5               **6a**     18
  4       **11b**   NH    *o*-Cl-Ph      Ph   5               **6b**     74
  5       **12b**   NMe   *o*-Cl-Ph      Ph   5               **6b**     24
  6       **13b**   O     *o*-Cl-Ph      Ph   5               **6b**     13
  7       **11c**   NH    *m*-Cl-Ph      Ph   5               **6c**     71
  8       **12c**   NMe   *m*-Cl-Ph      Ph   5               **6c**     38
  9       **13c**   O     *m*-Cl-Ph      Ph   5               **6c**     11
  10      **11d**   NH    *p*-Cl-Ph      Ph   5               **6d**     81
  11      **11e**   NH    *p*-Br-Ph      Ph   5               **6e**     77
  12      **11f**   NH    *p*-Me-Ph      Ph   5               **6f**     84
  13      **11g**   NH    *p*-OMe-Ph     Ph   5               **6g**     81
  14      **11h**   NH    *p*-CN-Ph      Ph   5               **6h**     73
  15      **11i**   NH    *p*-NO~2~-Ph   Ph   5               **6i**     69
  16      **11j**   NH    *m*-Cl-Ph      H    5               **6j**     71
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###### 

UV-Vis absorption maximum and fluorescence emission peak wavelength of luminol (**1**), pyrazolopyridopyridazine dione **6a** and *N*-aminopyrazolopyrrolopyridine dione **7a** in the different solvents.

  Compound          Solvent         λmax/nm of UV-Vis   λmax/nm of PL
  ----------------- --------------- ------------------- ---------------
  **6a**            Toluene         \- ^1^,366          469
  **6a**            THF             271,358             471
  **6a**            Ethyl acetate   268, 356            473
  **6a**            CH~2~Cl~2~      271, 350            483
  **6a**            MeCN            268, 351            488
  **6a**            Acetone         \- ^1^, 353         477
  **6a**            DMSO            264, 338            486
  **7a**            Toluene         286, ^1^ ,348       452
  **7a**            THF             264, 344            454
  **7a**            Ethyl acetate   262, 343            459
  **7a**            CH~2~Cl~2~      264, 344            471
  **7a**            MeCN            261, 329            425, 461
  **7a**            Acetone         \- ^1^, 338         452
  **7a**            DMSO            264, 335            429, 478
  Luminol (**1**)   DMSO            350                 392

^1^ It was overlapped with solvent absorption band.
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###### 

Quantum yields of fluorescence of luminol (**1**) and pyrazolopyridopyridazine diones **6a**, **6c**, and **6j**.

  Compound          Solvent         λ~fl~ ^1^/nm   Φ~f~ ^2^
  ----------------- --------------- -------------- ----------
  **6a**            CH~2~Cl~2~      481            0.056
  **6c**            CH~2~Cl~2~      472            0.067
  **6j**            CH~2~Cl~2~      450            0.140
  **6j**            THF             435            0.218
  **6j**            Toluene         438            0.209
  **6j**            Acetone         437            0.083
  **6j**            Ethyl acetate   437            0.049
  Luminol (**1**)   CH~2~Cl~2~      399            0.175

^1^ Fluorescence maximum wavelength (λ~fl~). ^2^ Φ~f~: Fluorescence quantum efficiency, relative to quinine sulfate (Φ~f~ = 0.60).
